S1 Fig: In vivo efficacy of thailanstatin MPP trastuzumab ADCs in N87 gastric cancer xenograft model (A) In vivo efficacy of MPP-ADC 13 and MPP-ADC 14 in ...
A
B
2500
2500
Vehicle ADC 13 (1.5 mg/kg)
Tumor Vol (mm3)
ADC 14 (1.5 mg/kg)
1500
1000
2000
Tumor Vol (mm3)
2000
ADC 13 (3mg/kg)
1500
Vehicle
1000 500 0
500
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45
Days 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 Days
S1 Fig: In vivo efficacy of thailanstatin MPP trastuzumab ADCs in N87 gastric cancer xenograft model (A) In vivo efficacy of MPP-ADC 13 and MPP-ADC 14 in N87 gastric cancer xenograft model dosed at 1.56 mg/kg (q4d x 4). (B) Individual mouse in vivo efficacy of MPP-ADC 13 in N87 gastric cancer xenograft model dosed at 3 mg/kg (q4d x 4) showing two complete regression. (C) Individual mouse in vivo efficacy of MPP ADC14 in N87 gastric cancer xenograft model dosed at 3 mg/kg (q4d x 4) showing three complete regression.
